Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis

被引：28

作者：

Müller, FMC

Kurzai, O

Hacker, J

Frosch, M

Mühlschlegel, F

机构：

[1] Univ Wurzburg, Dept Paediat, D-97080 Wurzburg, Germany

[2] Univ Wurzburg, Inst Mol Biol Infect, D-97080 Wurzburg, Germany

[3] Univ Wurzburg, Inst Hyg & Microbiol, D-97080 Wurzburg, Germany

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2001年 / 48卷 / 05期

关键词：

D O I：

10.1093/jac/48.5.713

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Micafungin (FK-463), a member of the new candin family of antifungal agents, was highly active against clinical isolates of Candida albicans and Candida dubliniensis. The in vitro activity of micafungin suggested that it was more potent than fluconazole, flucytosine, amphotericin B or voriconazole against C. albicans, and comparable or moderately less effective against C. dubliniensis isolates when high-resolution medium (HR) was used. Lower MICs of micafungin were recorded when RPMI 2% or AM3 2% media were used, indicating an influence of the growth medium on the MIC.

引用

收藏

页码：713 / 715

页数：3

相关论文

共 10 条

[1] Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus [J].

Chiller, T ;

Farrokhshad, K ;

Brummer, E ;

Stevens, DA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (12) :3302-3305

[2]

HICKS PS, 2000, 14 INT C ANT AG CHEM, P351

[3] Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis [J].

Ikeda, F ;

Wakai, Y ;

Matsumoto, S ;

Maki, K ;

Watabe, E ;

Tawara, S ;

Goto, T ;

Watanabe, Y ;

Matsumoto, F ;

Kuwahara, S .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (03) :614-618

[4] Growth medium effect on the antifungal activity of LY 303366 [J].

Klepser, ME ;

Ernst, EJ ;

Ernst, ME ;

Pfaller, MA .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1997, 29 (04) :227-231

[5] Molecular and phenotypic identification of the yeast pathogen Candida dubliniensis [J].

Kurzai, O ;

Korting, HC ;

Harmsen, D ;

Bautsch, W ;

Molitor, M ;

Frosch, M ;

Mühlschlegel, FA .

JOURNAL OF MOLECULAR MEDICINE-JMM, 2000, 78 (09) :521-529

[6] In vitro susceptibilities of Candida dubliniensis isolates tested against the new triazole and echinocandin antifungal agents [J].

Pfaller, MA ;

Messer, SA ;

Gee, S ;

Joly, S ;

Pujol, C ;

Sullivan, DJ ;

Coleman, DC ;

Soll, DR .

JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (03) :870-872

[7]

RODRIGUEZ A, 1995, VIS TECNOL, V2, P35

[8] EFFECTS OF CULTURE MEDIA ON THE INVITRO SUSCEPTIBILITY OF SELECTED OPPORTUNISTIC FUNGI TO FLUCONAZOLE AND ITRACONAZOLE [J].

SEKHON, AS ;

PADHYE, AA ;

GARG, AK ;

HAMIR, Z .

CHEMOTHERAPY, 1992, 38 (03) :169-173

[9] CANDIDA DUBLINIENSIS SP-NOV - PHENOTYPIC AND MOLECULAR CHARACTERIZATION OF A NOVEL SPECIES ASSOCIATED WITH ORAL CANDIDOSIS IN HIV-INFECTED INDIVIDUALS [J].

SULLIVAN, DJ ;

WESTERNENG, TJ ;

HAYNES, KA ;

BENNETT, DE ;

COLEMAN, DC .

MICROBIOLOGY-UK, 1995, 141 :1507-1521

[10] In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi [J].

Tawara, S ;

Ikeda, F ;

Maki, K ;

Morishita, Y ;

Otomo, K ;

Teratani, N ;

Goto, T ;

Tomishima, M ;

Ohki, H ;

Yamada, A ;

Kawabata, K ;

Takasugi, H ;

Sakane, K ;

Tanaka, H ;

Matsumo, F ;

Kuwahara, S .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (01) :57-62